Mako Surgical (MAKO) implodes after setting lower sales guidance for 2012. The company says that...

Mako Surgical (MAKO) implodes after setting lower sales guidance for 2012. The company says that after getting off to slow start for the year, it now expects to sell only 42-48 RIO systems during the year - instead of the 52-58 called for in prior guidance. Shares -33.7% AH.

Comments (8)
  • cyberbill1948
    , contributor
    Comments (4) | Send Message
    MAKO was a top pick by Motley Fool early in 2012. I am glad that I did not buy this stock.
    9 Jul 2012, 04:51 PM Reply Like
  • pbanados
    , contributor
    Comments (507) | Send Message
    I'll stop looking at Motley's picks. Just this year: First GMCR, next IPGP and RAX, now MAKO. Previously BIDU, among others. Dozens of failures, only successful case was ISRG, just because I sold it timely. Never have lost more money than with Motley's advices.
    In fact, my profits came precisely from what Motley denied for long time.
    9 Jul 2012, 05:49 PM Reply Like
  • njschultz
    , contributor
    Comments (4) | Send Message
    Yeah.............funny... their returns are 118 and 58 %. Of course that comes from buying many stocks and relying on a few winners to drive the portfolio. Not every stock can be a winner.
    10 Jul 2012, 02:59 AM Reply Like
  • Shamashm
    , contributor
    Comments (10) | Send Message
    Cyberbill, Its the second time they have dissapointed and in case you are unaware there is a class action against them which has also impacted stock performance:


    "The Complaint alleges that the Company and certain of its executive officers issued materially false and misleading statements and/or failed to disclose material adverse facts concerning MAKO’s business and financial prospects. Specifically, defendants misrepresented or failed to disclose that: (a) the Company was poised to suffer a larger first-quarter loss due to higher costs and slower sales of its RIO systems; (b) utilization rates were declining for the Company’s RIO systems; (c) the Company’s 2012 outlook, provided at the start of the Class Period, lacked a reasonable basis when made; and (d), based on the foregoing, defendants’ positive statements about the Company or its outlook lacked a reasonable basis."
    9 Jul 2012, 05:29 PM Reply Like
  • 1tallrn
    , contributor
    Comments (6) | Send Message
    I dumped it at 25 - THANK GOD - what a disappointment this stock has turned out to be because it is a solid product.
    9 Jul 2012, 06:27 PM Reply Like
  • bbbb2
    , contributor
    Comments (3) | Send Message
    I bought in when it was in the $40 range and them bought more when it pulled back into the $25 range. I believe the entire Board of Mako needs a strong look and a lot of changes need to be made. I believe in this product, but management doesn't seems to understand how grow this company. From what I read, which is now questionable, this product should almost sell itself. I feel people in sales are spending OUR money playing around seeing the world and not doing what they are getting paid to do. That would be, being seen, meeting with the people that are the ones that will be spending the money to buy this expensive, new, game changing medical product. I am about feed up with the CEO, COO, CFO, etc.
    Its time to get to work or get out the way!
    This is from a mad, frustrated investor who is ready to get off this roller coaster.
    10 Jul 2012, 02:20 AM Reply Like
  • johneewhy
    , contributor
    Comments (5) | Send Message
    Intersting and somewhat true comments about Motley. They have given me a few winners but far too many losers. As for Mako. I sold at 38 but plowed in recently at 25 and bought today at 15. The product is good. They need to learn how to sell it.
    10 Jul 2012, 10:20 AM Reply Like
  • Matthew Haith
    , contributor
    Comments (3) | Send Message
    may grab some at 10(if possible) stock up and ride it out long term 2-4 yrs great company crappy managment
    18 Jul 2012, 12:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs